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Objective. Use of in vitro chemoresponse assays for informing effective treatment selection is a compelling
clinical question and a topic of debate among oncologists. A prospective study was conducted evaluating the
use of a chemoresponse assay in recurrent ovarian cancer patients.
Methods.Womenwith persistent or recurrent ovarian cancer were enrolled under an IRB-approved protocol,
and fresh tissue sampleswere collected for chemoresponse testing. Patientswere treatedwith one of 15 protocol-
designated treatments empirically selected by the oncologist, blinded to the assay results. Each treatment was
classiﬁed by the assay as: sensitive (S), intermediate (I), or resistant (R). Patients were prospectively monitored
for progression-free survival (PFS) and overall survival (OS). Associations of assay response for the physician-
selected treatment with PFS and OS were analyzed.
Results.A total of 262 evaluable patientswere enrolled. Patients treatedwith an assay-sensitive regimendem-
onstrated signiﬁcantly improved PFS and OS while there was no difference in clinical outcomes between I and R
groups. Median PFS was 8.8 months for S vs. 5.9 months for I + R (hazard ratio [HR] = 0.67, p = 0.009). The
association with assay response was consistent in both platinum-sensitive and platinum-resistant tumors (HR:
0.71 vs. 0.66) and was independent of other covariates inmultivariate analysis (HR = 0.66, p = 0.020). A statis-
tically signiﬁcant14-month improvement in mean OS (37.5 months for S vs. 23.9 months for I + R, HR = 0.61,
p = 0.010) was demonstrated.
Conclusions. This prospective study demonstrated improved PFS and OS for patients with either platinum-
sensitive or platinum-resistant recurrent ovarian cancer treated with assay-sensitive agents.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.15203, USA. Fax: +1 866 243 2424.
c.Open access under CC BY license.
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Epithelial ovarian cancer (EOC) is the leading cause of gynecologic
cancer mortality in the United States [1]. Despite the achievement of
high response rates, improvements in survival with aggressive surgical
debulking and use of platinum/taxane combination chemotherapy, the
disease recurs in the majority of the patients [2]. Recurrent EOC has
many treatment options depending on speciﬁc aspects of its presen-
tation, including secondary cyto-reductive surgery and numerous
second-line chemotherapy treatment options. While most patients
eventually succumb to progression of recurrent disease, manywill ben-
eﬁt from therapy and experience prolonged remissions and symptom-
free survival [2,3]. Patients experiencing a relapse greater than sixmonths
following ﬁrst-line platinum-based treatment have been deﬁned
“platinum-sensitive” and have signiﬁcant responses to further
platinum-based combination therapies [4,5]. The response rate increases
in relation to theplatinum-free interval such that those relapsing greater
than 24 months from initial treatment are similar to chemo-naïve
patients with respect to response [4,5]. Patients experiencing disease
progression within 6 months from the completion of ﬁrst-line chemo-
therapy are deﬁned as platinum-resistant [4,5] and are typically treated
withmultiple single agent therapies. Expected progression-free survival
(PFS) and overall survivals (OS) are signiﬁcantly compromised for this
group of patients.
Due to the inherent challenges of multiple treatment variables, costs
and time necessary to conduct large prospective clinical trials in
recurrent EOC [6], prior studies evaluating chemoresponse assays have
been largely retrospective. Furthermore, ﬁndings from several retro-
spective studies have been inconsistent in the demonstration of correla-
tion between assay results and treatment outcomes in EOC [7–11],
triggering debate over the use of assay-informed treatment in EOC
[12]. Many of these studies had small sample size cohorts, lacked
detailed information and were missing the necessary patient follow-
up that clinical trials require. Even those studies that were of a larger
scale did not always yield the level of evidence necessary to validate
the use of chemoresponse assays in ovarian cancer [9,13,14]. Still,
several large, retrospective clinical studies have demonstrated that
chemoresponse assays are clinically feasible, correlate with treatment
outcomes, and may have the potential to aid in the prioritization of
drug therapies [15]. Speciﬁcally, Gallion et al. [10] reported that patients
treated with an assay-sensitive regimen had progression-free intervals
three times longer than those who received an assay-resistant treat-
ment, and OS was more than double for assay-sensitive patients in a
subsequent analysis [11]. For these reasons, a prospective, multi-site,
non-interventional (blinded to avoid physician treatment bias) clinical
trial was conducted to evaluate the ability of a chemoresponse assay
to identify treatments that may lead to improvement in PFS and OS.
The study results reported herein are in compliance with REMARK [16]
and STARD [17] guidelines.
Patients and methods
Patient eligibility
Patients with histologically conﬁrmed EOC, fallopian tube (FTC),
or primary peritoneal cancer (PPC) were enrolled at 35 sites across
the United States. Eligible patients received ≤2 prior chemotherapy
regimens and experienced persistent, recurrent or progressive
disease as documented by imaging or by an increased level of CA-125.
Both platinum-sensitive (platinum-free interval [PFI] ≥ 6 months)
and platinum-resistant (PFI b 6 months) diseases, based on clinical
outcomes following treatment in the primary setting, were included.
Other eligibility criteria included ≥18 years of age, ECOG performance
status ≤2, adequate bone marrow, renal and hepatic function, and
viable tumor tissue available for chemoresponse assay from surgical
excision or drainage of ascites/effusions.Treatment and follow-up
This study was designed to be non-interventional in order to assess
the assay-outcome correlation in an unbiased manner. Patients were
treated with one of 15 prospectively-speciﬁed protocol treatments,
based on the medical judgment of the oncologist (i.e. patients and phy-
sicians were blinded to the assay results for the initial protocol treat-
ment). Treatment was required to begin within 8 weeks of sending
tissue for in vitro testing. Once disease progression was demonstrated
with the treatment selected for the study, there were no exclusions
from further therapy, and the physician could optionally gain access to
the assay results (physicians requested access to assay results, post pro-
gression, for 32% of the evaluable patients). Supportive care was also
allowed at the discretion of the treating physician. Disease progression
wasmeasured by radiologic examination (CT scan as the primary imag-
ing method), physical examination, and CA-125 measurements using
RECIST or GCIC criteria, and the assessment was performed every
other cycle during the treatment, every 3 months for the ﬁrst 2 years,
every 6 months for the next 3 years and annually thereafter.
Chemoresponse assay
Fresh tissue samples were collected from each patient at the time of
recurrence for in vitro testing (ChemoFx®, Precision Therapeutics, Inc.,
Pittsburgh, PA). Details regarding the assay procedure have been
described elsewhere [18]. In brief, primary cultures were initiated by
mincing each tissue sample into 1 mm3 explants, which were then
seeded into culture ﬂasks. Upon near conﬂuency, primary cultures
were trypsinized and seeded into 384-well microtiter plates (Corning,
Lowell, MA) at 8000 cells/mL and used immediately for in vitro testing.
Ten concentrations of each treatment were prepared by serial dilution.
Each concentration was added to three replicate wells on themicrotiter
plate; three replicates of control (no treatment) wells were associated
with each treatment also. Culture seeding into microtiter plates, as
well as serial treatment dilution and application, were completed
using highly automated liquid handling robotics. After 72 h of incuba-
tion with treatment, surviving adherent cells were stained with DAPI
(Molecular Probes, Carlsbad, CA) and counted using proprietary, auto-
mated computer-assisted microscopy (Precision Therapeutics, Inc.,
Pittsburgh, PA) [19]. The inhibition of tumor growth was measured for
each concentration (average of cell counts in three replicates) of a
given treatment. The survival fraction (SF) of tumor cells at each con-
centration was calculated as compared to control (no treatment). The
summation of SF values over concentrations 1 through 7was computed
as the drug response score,which represents the area under thedose re-
sponse curve (deﬁned as AUC7 score hereafter). A smaller AUC7 score
indicates that a tumor is more sensitive to a treatment in vitro; a larger
score indicates greater resistance to a treatment. For each treatment,
in vitro tumor response was classiﬁed into one of three categories
according to the AUC7 score: sensitive (S), intermediate (I), and resis-
tant (R). The cut-point thresholds for the classiﬁcationswere previously
and independently established based on the 25th and 75th AUC7 per-
centiles in external and independent recurrent EOC patients.
Statistical analysis
The primary endpoint of this study was PFS, deﬁned as the length of
time from the start of recurrence chemotherapy selected by the physi-
cian for this study until the date of ﬁrst documented disease progression
or death;OSwas the secondary endpoint. The studywas designed to de-
tect a hazard ratio (HR) of 0.6 at a power of 0.80 (α = 0.05), requiring
256 patients with 80% of the patients experiencing disease progression
or death. PFS was estimated by the Kaplan–Meier procedure, and the
difference between in vitro response categories was compared using
the log-rank test. The association of in vitro assay results and PFS was
also assessed using the Cox regression model adjusted for clinical
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others], tumor grade [grade 3 vs. grades 1–2] and platinum sensitivity
status [platinum-sensitive vs. platinum-resistant]) [20]. TheHRof disease
progression for S vs. I + R was estimated. Planned, non-powered sub-
group analyses for platinum-sensitive and platinum-resistant patients
were also conducted. The analyses for OS were employed using the
same approaches. All of the analyses were conducted using the assay
treatment that was an exact match of the patient (clinical) treatment.
Results
Patients
Between 2004 and 2011, 335 eligible patients were enrolled, and
262 (78%) had both a successful assay and complete clinical data, mak-
ing them evaluable for this study. Seventy-three (22%) patients were
excluded, primarily due to lack of growth of a sufﬁcient number of ma-
lignant cells in culture (n = 34) and quality control failure (n = 21).
The majority of tissue was submitted as biopsies (93%), with the
remaining 7% being in the form of ascites ﬂuid. Patient characteristics
are summarized in Table 1 and Table S2. The majority of the tumors
were high-grade papillary serous, and 55% of patients had platinum-
sensitive recurrent EOC. A broad range of chemotherapieswas adminis-
tered based on the medical judgment of the treating physicians,
covering 12 distinct treatments (encompassing both single agents and
2 agent combinations); docetaxel, cisplatin/docetaxel, and cisplatin/
topotecan were available for use in this study but were not adminis-
tered clinically to any of the evaluable patients (Table 2). All patients
were treatedwith at least one cycle of the physician selected treatment,
with half of the patients in the cohort completing at least 4 treatment
cycles (range: 1–13). For platinum-sensitive tumors, carboplatin/
paclitaxel (31%), PLD (15%) and carboplatin/gemcitabine (12%)
were most frequently used, while carboplatin/paclitaxel (29%), PLD
(28%) and topotecan (13%) were usually offered to persistent orTable 1
Patient characteristics.
No. of patients %
Age (years)
b50 38 (14.5)
50–59 79 (30.2)
60–69 80 (30.5)
≥70 65 (24.8)
Median (range) 61 (24–93)
Race
Caucasian 234 (89.3)
African American 14 (5.3)
Others 14 (5.3)
ECOG performance status
0 183 (69.9)
1 66 (25.2)
2 13 (5.0)
Histology
Serous 178 (67.9)
Endometrioid 19 (7.3)
Clear cell 19 (7.3)
Mucinous 3 (1.3)
Adenocarcinoma, NOS 30 (11.5)
Others 13 (5.0)
Tumor grade
1 12 (4.6)
2 33 (12.6)
3 168 (64.1)
Unknown 49 (18.7)
Platinum sensitivity status
Platinum-sensitive 145 (55.3)
Platinum-resistant 117 (44.7)platinum-resistant recurrent tumors (Table S1). It is interesting to
note that no single treatment accounted for more than 30% of the
treatments assessed in this study, demonstrating the lack of a stan-
dard of care in this indication. Furthermore, the distribution of treat-
ments across S and I + R patient cohorts is not materially different
from one another (Table 2), supporting the notion that different pa-
tients respond differently to various therapies and that no one treat-
ment generally outperforms the others.
Across the entire study cohort, the median follow-up time was
29 months (range: 1–71 months), based on achievement of the prima-
ry endpoint, PFS. At study closure, 33 (12.6%) patients were alive with-
out disease progression, 67 (25.6%) were alive with progression, and
162 (61.8%) were deceased. The median PFS for the total study popula-
tion was 6.7 months and the median OS was 26.5 months. The median
PFS for platinum-sensitive and platinum-resistant patients were
9.3 months and 3.8 months (p b 0.001), respectively; and the median
OS were 33.6 months and 21.8 months (p b 0.001), respectively.Chemoresponse assay and clinical outcomes
For the 262 patients, the assay result for the treatment received clin-
ically was S (28.6%), I (45.8%) or R (25.6%). There were no signiﬁcant
differences in patient characteristics across the three groups, except
for age, with the S group being younger than I + R patients (57 vs.
63 years, p b 0.001).
From univariate analysis, patients with tumor response deﬁned as S
for their clinical treatment demonstrated signiﬁcantly improved PFS
[median PFS 8.8 months for S vs. 5.9 months for I + R (HR = 0.67,
95% CI = 0.50–0.91, p = 0.009)] (Fig. 1A). There was no difference in
PFS between the I and R groups (HR = 0.92, 95% CI = 0.67–1.26,
p = 0.591). The associationwith in vitro responsewas consistentwith-
in platinum-sensitive and platinum-resistant subpopulations as well
(HR: 0.71 vs. 0.66, respectively; p = 0.690 for interaction test), showing
improved outcomes when using S regimens in either cohort (Fig. 2). In
multivariate analysis, platinum sensitivity status and in vitro assay
results remained the only two independent factors signiﬁcantly associ-
ated with PFS (Table 3). Age did not remain signiﬁcant in multivariate
analysis. Speciﬁcally, patients deﬁned as S had a 34% reduced risk of dis-
ease progression compared to those deﬁned as I or R, when controlling
for age, performance status, histology, tumor grade and prior platinum
sensitivity status (HR = 0.66, 95% CI = 0.47–0.94, p = 0.020). A simi-
lar correlation was identiﬁed for OS (median OS: 37.5 months for S vs.
23.9 months for I + R, HR = 0.61, 95% CI = 0.41–0.89, p = 0.010;
Fig. 1B) and the relationship was consistent in multivariate analysis
(HR = 0.59, 95% CI = 0.38–0.93, p = 0.023; Table 3).Table 2
Distribution of treatment selection by assay result.
Therapya No. of patients (%)
S I + R All
Carboplatin/paclitaxel 27 (36.0) 52 (27.8) 79 (30.2)
PLD 11 (14.7) 44 (23.5) 55 (21.0)
Carboplatin/gemcitabine 13 (17.3) 12 (6.4) 25 (9.5)
Topotecan 5 (6.7) 17 (9.1) 22 (8.4)
Carboplatin 6 (8.0) 9 (4.8) 15 (5.7)
Carboplatin/docetaxel 2 (2.7) 13 (7.0) 15 (5.7)
Cisplatin/gemcitabine 2 (2.7) 13 (7.0) 15 (5.7)
Cisplatin/paclitaxel 2 (2.7) 11 (5.9) 13 (5.0)
Gemcitabine 2 (2.7) 7 (3.7) 9 (3.4)
Carboplatin/topotecan 3 (4.0) 2 (1.1) 5 (1.9)
Paclitaxel 1 (1.3) 4 (2.1) 5 (1.9)
Cisplatin 1 (1.3) 3 (1.6) 4 (1.5)
a Docetaxel, cisplatin/docetaxel and cisplatin/topotecan were also available for use in
this study but were not clinically administered to any of the evaluable patients.
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Fig. 1. PFS (A) and OS (B) in recurrent ovarian cancer patients treated with assay S versus
I + R treatments. Patients treatedwith assay S treatments (n = 75) experienced amedi-
an PFS of 8.8 months andmedian OS of 37.5 months, while those treatedwith assay I or R
treatments (n = 187) experienced a median PFS of 5.9 months and median OS of
23.9 months.
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Fig. 2. PFS in platinum-sensitive (A) and platinum-resistant (B) recurrent ovarian cancer
patients treatedwith assay S versus I + R treatments. Platinum-sensitive patients treated
with assay S treatments (n = 46) experienced a median PFS of 10.0 months, while those
treated with assay I or R treatments (n = 99) experienced a median PFS of 9.0 months.
Platinum-resistant patients treated with assay S treatments (n = 29) experienced a me-
dian PFS of 5.2 months, while those treatedwith assay I or R treatments (n = 88) experi-
enced a median PFS of 3.5 months.
Table 3
Multivariate analysis of factors affecting PFS and OS.
PFS OS
HRa (95% CI) p value HRa (95% CI) p value
Age
Inc. per 10 years 1.07 (0.93–1.23) 0.360 1.03 (0.87–1.22) 0.744
ECOG PS
1 or 2 vs. 0 1.12 (0.80–1.57) 0.437 1.30 (0.86–1.95) 0.209
Histology
Serous vs. others 1.36 (0.96–1.93) 0.082 1.09 (0.73–1.63) 0.684
Tumor grade
3 vs. 0 or 1 1.13 (0.78–1.63) 0.530 1.20 (0.75–1.90) 0.444
Platinum sensitivity status
Plat sensitive vs. plat
resistant
0.64 (0.47–0.87) 0.004 0.66 (0.45–0.96) 0.029
Chemoresponse assay results
S vs. I or R 0.66 (0.47–0.94) 0.020 0.59 (0.38–0.93) 0.023
a Hazard ratio (HR) estimated from proportional hazardsmodel adjusted for covariates.
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To estimate the proportion of patients that may beneﬁt from an S
treatment chosen prospectively, the in vitro drug responses to seven
single agents (carboplatin, cisplatin, gemcitabine, PLD, paclitaxel,
docetaxel and topotecan) were analyzed (Fig. 3). These seven agents,
alone or in combination, encompass the 15 treatments included in this
study. The current analysis was conducted on the single agents in order
to elucidate the mechanism of action of each drug individually. For
patients with complete assay data for all seven of these agents (n =
208), 48% of tumors were either I or R to all seven agents, whereas 10%
were S to all. The remainder of the patients (42%) were S to between 1
and 6 agents, suggesting that although cross-resistance is considered to
be common in persistent or recurrent EOC, a relatively large number of
patients (more than half) may beneﬁt from assay-informed individual-
ized chemotherapy.
Discussion
Currently, empiric treatment of recurrent EOC, FTC, and PPC is
based primarily on the patient's treatment free interval, anticipated
toxicities, the availability of clinical trials using notice agents, and
population response rates from phase II and III clinical trials, as the
response rates are relatively modest across the various treatment
options. However, as many as 20 different clinically-acceptable and
equivalent treatment choices are identiﬁed in current treatment
guidelines [21], with insufﬁcient evidence to indicate that any oneagent is superior to any other. Additionally, in EOC, unlike some other
solid tumors, there is a lack of validated biomarkers that stratify patients
for individualized treatment choices, and population-based studies con-
tinue to be the primary source of information for physicians' empiric
treatment decisions. Although a prospective, randomized trial has
R7
8%
I/R
40%
S1
11%
S2
9%
S3
8%
S4
5%
S5
5%
S6
4% S7
10%
Fig. 3. Distribution of assay results across seven single agent treatments (carboplatin, cis-
platin, gemcitabine, PLD, paclitaxel, docetaxel, topotecan). Patients (n = 208) were cate-
gorized as resistant to all 7 treatments (R7), intermediate or resistant to all 7 treatments (I/
R), or sensitive to anywhere from 1 (S1) to 7 (S7) treatments.
366 T. Rutherford et al. / Gynecologic Oncology 131 (2013) 362–367been previously reported, neither the PFS nor the OS results achieved a
level of signiﬁcance, possibly due, in part, to a physician “learning effect”
associated with a randomized trial designwhere one arm of the study is
treated empirically [22]. Several investigators have commented on pro-
posals for prospective clinical trial designs evaluating biomarkers and
concluded that a 2-arm (empiric vs. marker) trial design, such as that
attempted by Cree et al. [22] is largely impractical due to the large sam-
ple size demanded, cross-arm treatment overlap (i.e. inefﬁciency), po-
tential for physician treatment bias, and other logistical and pragmatic
concerns [23–26].
The current study evaluates the correlation of chemoresponse assay
results to treatment outcomes, with therapies chosen by oncologists
that were blinded to the assay results. This study is the ﬁrst clinical
trial of this design conducted to our knowledge.
This study demonstrates that patients who were treated with an
assay-sensitive regimen had an improvement in both PFS and OS
compared to patients who were treated with assay-resistant regimens
(Table 3). This signiﬁcant (≥50%) improvement in both PFS and OS
represents an OS increase of 14 months. Importantly, these observed
improvements in PFS and OS were evident in both the platinum-
sensitive and platinum-resistant subgroups. Ideally, the follow-up time
would be further extended for enhanced assessment of OS; this may be
undertaken in a future analysis. In addition, the contribution of further
treatments (subsequent to the treatment selected for this study)
towards OS is unknown. However, if a sensitive treatment had followed
a resistant study treatment, or vice versa, then the difference in OS (and
associatedHR) between S and I + R armswould have been smaller than
reported herein. So, while this study focused on patient progression on
the study treatment, and information regarding further treatments (in-
cluding whether or not results from the chemoresponse assay were
used to inform those subsequent treatment decisions)was not collected,
the 14 month improvement in OSmay be further increased with utiliza-
tion of assay-informed treatments at future recurrence(s).
It is important to emphasize that, consistentwith clinical studies in a
mixed population of platinum-sensitive and -resistant patients [27,28],
approximately 25 to 30% of the patients were clinically responsive to
their empirically selected treatment (Table 2). Another 25% of the
patients tested S to at least one of the 15 protocol therapies in the
assay, but were treated with an I or R therapy empirically. Therefore,
more than 50% of the tumors were found to be S to at least one drug
tested in vitro (Fig. 3), suggesting that although resistance is common
in recurrent EOC, a majority of patients may beneﬁt from assay-
informed individualized chemotherapy. In otherwords, if the oncologists
had not been blinded to the results of the chemoresponse assay in this
study, the number of patients who could have beneﬁtted from an S
treatment would have more than doubled. In clinical practice this sce-
nario is frequently encountered when oncologists must choose between
seemingly equivalent therapies in platinum-sensitive recurrent EOC
(e.g. carboplatin in combinationwith PLD vs. gemcitabine vs. paclitaxel).Furthermore, current chemoresponse assays are not compatible with
directly assaying the efﬁcacy of anti-angiogenic therapy due to the
focus on epithelial (malignant) cell response to chemotherapy and the
associated lack of (intact) endothelial cells in culture on which anti-
angiogenic therapies act. Thus, given the recently demonstrated beneﬁts
of adding anti-angiogenic therapy (bevacizumab) to standard cytotoxic
chemotherapy in ovarian cancer [29–32], chemoresponse assays may
be used to inform decisions on which cytotoxic therapy to couple with
anti-angiogenic therapy.
ChemoFx®, the chemoresponse assay employed in the current
study, has been previously evaluated in retrospective studies inclusive
of both primary and recurrent EOC [10,11]. These promising results
warranted further evaluation in the form of this current prospective,
multi-site, non-interventional trial. Moreover, a subgroup analysis
conducted herein demonstrated an association between assay results
and clinical outcome in both platinum-sensitive and -resistant patients;
assay association with clinical response was also independent of
platinum-sensitive or -resistant status (as well as all other clinical
covariates) in multivariate analysis. A previous study using a differ-
ent chemoresponse assay showed a correlation between PFS and
assay results in platinum-sensitive patients but not in patients with
platinum-resistant disease [33]. Because recommended treatment
options differ between these two subgroups, demonstrated performance
of a chemoresponse assay in both groups of patients with recurrent EOC
is clinically useful.
In conclusion, this multi-institutional prospective study demon-
strates that recurrent ovarian cancer patients who were treated with a
regimen identiﬁed as sensitive by a chemoresponse assay experienced
signiﬁcantly improved PFS and OS of 3 and 14 months, respectively.
These results are in notable contrast tomultiple, randomized drug stud-
ies in this indication that have repeatedly shown little or no difference
between various treatment regimens. Results from this study indicate
that a chemoresponse assay may be a very useful tool for optimizing
treatment selection when there are multiple clinically-acceptable and
-equivalent treatments available, and few, if any, biological markers
that can reliably assist in a more individualized treatment plan. When
treatments are individualized, even though the same regimens are
used clinically, patients experience marked improvements in outcome.
Furthermore, the results suggest that effective (sensitive) treatment
options could be available for many more patients than is currently
achieved by empiric treatment. These compelling data suggest that
it may be reasonable to prospectively utilize chemoresponse assays
to assist clinicians in the optimal prioritization of therapy for both
platinum-sensitive and platinum-resistant patients with recurrent EOC.
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